'Sleepy' FDA panel backs BI's Spiriva Respimat
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim easily convinced an FDA panel of outside advisers on 14 August to back approval of the firm's latest chronic obstructive pulmonary disease (COPD) drug Spiriva Respimat (tiotropium bromide), with the committee voting 10-3 at a meeting that could almost be described as sleepy.